31 results
8-K
CCCC
C4 Therapeutics Inc
8 Mar 24
Departure of Directors or Certain Officers
4:10pm
(the "Retention Period"), the option holder either: (i) is terminated by the Company for cause or resigns from the Company, except by reason of death
8-K
EX-99.1
CCCC
C4 Therapeutics Inc
11 Jan 24
Regulation FD Disclosure
7:05am
Activate Fully Differentiated T-cells Regulate Hematopoietic Stem Cell Differentiation Consequences of IKZF1/3 Degradation: MM and NHL Cell Death T
8-K
EX-99.1
CCCC
C4 Therapeutics Inc
12 Dec 23
Regulation FD Disclosure
4:28pm
Differentiation Consequences of IKZF1/3 Degradation: MM and NHL Cell Death T-cell Activation On-target Neutropenia CD8+ activated CD8+ MM and NHL Cells 10 … = 22) Ongoing, n (%) 3 (14%) Discontinued, n (%) Progressive disease, n(%) Physician decision, n(%) Withdrawal by patient, n(%) Death, n (%) Adverse
8-K
CCCC
C4 Therapeutics Inc
20 Nov 23
C4 Therapeutics Strengthens Board of Directors with Owen Hughes Appointment
7:05am
thereafter until his successor has been duly elected and qualified or until his earlier death, removal or resignation.
In connection with his
8-K
z3s2f
2 Aug 22
C4 Therapeutics Appoints Experienced Clinical Development Leaders Laura Bessen, M.D. and Donna Grogan, M.D. to Board of Directors
8:33am
8-K
EX-99.1
ipkweevcbv
8 Apr 22
C4 Therapeutics Presents Clinical Data from Cohort A of the Ongoing Phase 1/2 Clinical Trial of CFT7455, a Novel IKZF1/3 Degrader
1:21pm
8-K
54z8r8
16 Mar 22
C4 Therapeutics Appoints Utpal Koppikar to Board of Directors
4:15pm
8-K
EX-99.2
bp9 y7ndpaxijwyvurz
26 May 21
Regulation FD Disclosure
4:28pm
8-K
EX-99.1
er9eiy1tas f7r0kn
13 May 21
C4 Therapeutics Reports Recent Business Highlights and First Quarter 2021 Financial Results
4:22pm
8-K
4roiw tbot
11 Mar 21
C4 Therapeutics Reports Recent Business Highlights and Full Year 2020 Financial Results
4:10pm
8-K
EX-99.1
15mib2rv70qkall2plxq
19 Nov 20
Regulation FD Disclosure
5:00pm
8-K
EX-3.1
mcteyt2l8i
6 Oct 20
Departure of Directors or Certain Officers
4:46pm
424B4
ko5pnvru1 n6qqm72k
2 Oct 20
Prospectus supplement with pricing info
5:10pm
S-1/A
EX-10.2
h1wdd1 sr
28 Sep 20
IPO registration (amended)
6:07am
S-1/A
EX-10.3
lii95kp g8jb0vu
28 Sep 20
IPO registration (amended)
6:07am
S-1/A
20qt9ufh4hxl4iq
28 Sep 20
IPO registration (amended)
6:07am
S-1
EX-3.3
zoolwgad61t9zj43u
10 Sep 20
IPO registration
5:26pm
S-1
EX-10.1
223yet
10 Sep 20
IPO registration
5:26pm
S-1
EX-10.14
b4kvn4412u1
10 Sep 20
IPO registration
5:26pm